## **GLUCAGON (B2)**

(Revised: January 2010)



TYPE:		Pancreatic hormone [S4]		
PRESENTATION:		Vial containing 1 International Unit of glucagon as a dry powder, with a syringe containing 1ml of diluting solution		
ACTION:		Causes the liver to metabolise stores of glycogen to glucose, resulting in a rise in the blood glucose level.		
		Only	effective if liver glycogen is available.	
		Onset IM: 5 – 20 minutes		
USE:		ICP	Treatment of hypoglycaemia (BGL <4mMol/l), when oral or IV glucose cannot be administered.	АР
ADVERSE EFFECTS:		Very rare.		
		1. Nausea and vomiting		
		2. Very occasionally, hypersensitivity		
CONTRA- INDICATION:		Known hypersensitivity		
DOSE:				
ADULT:				
ICP 1 International U		l Unit	Unit (IU) – IM. Single dose only.	
PAEDIATRIC:				
ICP	Weight <20kg (approx 5yrs): 0.5 IU – IM. Single dose only.			

**NOTE:** Patients who respond to glucagon should eat, to prevent later development of further hypoglycaemia.

Recheck BGL following treatment.

Weight >20kg: 1 IU – IM. Single dose only.